NPI-001
Retinitis Pigmentosa
Phase 2/3Active
Key Facts
About Nacuity Pharmaceuticals
Nacuity Pharmaceuticals is a privately held, Fort Worth-based biotech founded in 2017, targeting oxidative stress as a root cause of disease. The company is advancing a pipeline of first-of-a-kind small molecule therapies, with its most advanced program, NPI-001, in Phase 2/3 development for retinitis pigmentosa. Led by a seasoned team with deep expertise in ophthalmology and drug development, particularly from Alcon Laboratories, Nacuity aims to deliver disease-modifying treatments for underserved patient populations. Its platform has potential applications beyond ophthalmology into other chronic conditions driven by oxidative damage.
View full company profileTherapeutic Areas
Other Retinitis Pigmentosa Drugs
| Drug | Company | Phase |
|---|---|---|
| Endogena Therapeutics Program | Centenara Labs | Phase 1b/2a |
| BS01 | Bionic Sight | Phase 1/2 |
| jCell | jCyte | Phase 3 |
| EA-2353 | Endogena Therapeutics | Phase I/IIa |
| MCO-010 | Nanoscope Therapeutics | Phase 2/3 |
| RTx-015 | Ray Therapeutics | Phase 1 |
| OCU400 | Ocugen | Phase 3 |
| ADX-2191 | Aldeyra Therapeutics | Phase 2 |